Literature DB >> 20135584

[Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra].

A K Klein1, G Horneff.   

Abstract

Muckle Wells syndrome is an autoinflammatory disease in the group of cryopyrin associated periodic syndromes (CAPS). We report the case of an 8 year old girl with MWS who presented with remitting fever, urticaria, remitting coxitis, osteitis, bilateral uveitis anterior, elevated levels of C-reactive protein (CRP) and Serum amyloid A (SAA) and progressive sensoneurinal hearing loss. After starting treatment with anakinra, clinical symptoms dissolved almost completely for about two years now. CRP and SAA levels normalized quickly and sustained and as a consequence the risk of amyloidosis may be minimized. Notable is the complete recovery from sensoneurinal hearing loss merely two months after start of treatment. This brings up questions about pathophysiology of sensoneurinal hearing loss in MWS and emphasizes the benefits of an early diagnosis, as an early start of treatment possibly reduces long-term damage. (c) Georg Thieme Verlag KG Stuttgart-New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135584     DOI: 10.1055/s-0029-1239527

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  9 in total

1.  Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation.

Authors:  J Rech; B Manger; B Lang; G Schett; M Wilhelm; J Birkmann
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

Review 2.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

3.  Treatment of Inflammatory Diseases with IL-1 Blockade.

Authors:  Charles A Dinarello
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-03-07

Review 4.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 5.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 6.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

Review 7.  Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?

Authors:  Tatjana Welzel; Jasmin B Kuemmerle-Deschner
Journal:  J Clin Med       Date:  2021-01-01       Impact factor: 4.241

8.  Early detection of sensorineural hearing loss in Muckle-Wells-syndrome.

Authors:  Jasmin B Kuemmerle-Deschner; Assen Koitschev; Pascal N Tyrrell; Stefan K Plontke; Norbert Deschner; Sandra Hansmann; Katharina Ummenhofer; Peter Lohse; Christiane Koitschev; Susanne M Benseler
Journal:  Pediatr Rheumatol Online J       Date:  2015-11-04       Impact factor: 3.054

Review 9.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.